Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 6/20 | 0.61 |
| ▸ | TNF | P01375 | 2/20 | 0.60 |
| ▸ | MDM4 | O15151 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | CASP3 | P42574 | 2/20 | 0.50 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8223034 | 0.96 | TLR2 (0.56) | TLR2TNFMDM4TP53CASP3 | |
| SCHEMBL10081723 | 0.96 | TLR2 (0.56) | TLR2TNFMDM4TP53CASP3 | |
| SCHEMBL30824463 | 0.96 | TLR2 (0.56) | TLR2TNFMDM4TP53CASP3 | |
| SCHEMBL29613683 | 0.87 | CASP3 (0.55) | TLR2TNFMDM4TP53CASP3 | |
| SCHEMBL30656568 | 0.87 | MDM4 (0.59) | TNFMDM4TP53CASP3MDM2 | |
| SCHEMBL20357051 | 0.86 | TLR2 (0.66) | TLR2TNFMDM4TP53CASP3 | |
| SCHEMBL18614182 | 0.86 | TLR2 (0.66) | TLR2TNFMDM4TP53CASP3 | |
| SCHEMBL16744148 | 0.86 | TLR2 (0.66) | TLR2TNFMDM4TP53CASP3 | |
| SCHEMBL15083321 | 0.86 | TLR2 (0.66) | TLR2TNFMDM4TP53CASP3 | |
| SCHEMBL16744149 | 0.86 | TLR2 (0.66) | TLR2TNFMDM4TP53CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287131-A1 | PEPTIDE | AGC Inc. (JP) | 2024-08-29 | — | — | US | disclosed |
| EP-4406961-A1 | PEPTIDE | AGC INC. (JP) | 2024-07-31 | — | — | EP | disclosed |
| WO-2023048236-A1 | PEPTIDE | ＡＧＣ株式会社 | 2023-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287131-A1 | PEPTIDE | SSTR5, SSTR4, NGLY1 | TLR2 3625/4885TNF 3946/4885MDM4 1923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.